Hikma Pharmaceuticals completed the acquisition of the US finished dosage form business of Xellia Pharmaceuticals for $185m.

Hikma Pharmaceuticals, a British multinational pharmaceutical company, completed the acquisition of the US finished dosage form business of Xellia Pharmaceuticals, a Copenhagen based specialty company focusing on providing anti-infective treatments and other critical care therapies, for $185m. "Hikma has grown to become a top-three US supplier of sterile injectable medicines thanks to our strong record of successfully making value-enhancing acquisitions like this one. This acquisition will add significant scale to our US operations and will enhance our US injectable manufacturing capabilities and portfolio by adding complex technologies. I am confident that this transaction will deliver significant future value to our Injectables business, supporting growth over the medium term," Riad Mishlawi, Hikma CEO.